Redwood AI's Expanding War Chest of Ambition Collides With a Shrinking Cash Pile

Redwood AI Corp. pursues Quantum.IQ takeover and AI partnerships but faces zero revenue, $10.93M loss, and a 19% stock drop. Cash reserves dwindle to $2.22M.

For a company that has yet to record a single dollar of revenue, Redwood AI Corp. is piecing together an impressive puzzle of partnerships, patents, and potential acquisitions. Yet the stock tells a more sobering story: shares have tumbled 19% over the past seven days, closing Tuesday at 3.25 CAD on the Canadian Securities Exchange after a modest intraday bounce. The current price is a far cry from the all-time high of 10.10 CAD touched just two months ago in late April.

At the centre of the narrative sits the proposed takeover of Quantum.IQ, a Vancouver-based developer of post-quantum cryptography security software tailored for government agencies, defence organisations, and critical infrastructure operators. Redwood has signed a non-binding letter of intent to acquire all outstanding Quantum.IQ shares in exchange for issuing up to 14 million of its own common shares, with milestone-based components and staggered lock-up periods baked in. The deal remains contingent on due diligence, definitive agreements, and clearance from the Canadian Securities Exchange — meaning execution is far from assured.

Alongside the quantum bet, Redwood is stitching together a web of law-enforcement and scientific collaborations. In April it announced a partnership with Aidos Innovations to build an AI-powered analytical platform for detecting toxic opioids, drawing in the Royal Canadian Mounted Police, Canada Border Services Agency, Victoria Police, and a track-and-trace initiative backed by the province of British Columbia. The company is also advancing its Q-SAFE program for classifying hazardous chemicals, supported by the National Research Council of Canada's Industrial Research Assistance Program.

On the research front, Redwood's Reactosphere chemical-reaction prediction platform has seen its training dataset swell from roughly 4 million to more than 21 million examples through a cooperation with the University of British Columbia. In May the company added a partnership with Resilience Biosciences to apply Reactosphere to small-molecule drug development. And in June, Redwood filed a provisional patent application with the US Patent and Trademark Office for a technology that uses model-driven planning to optimise chemical experiments — relevant to pharmaceuticals, materials science, and defence-related chemistry.

None of this progress, however, masks the deteriorating financial reality. In the half-year ended February 2026, Redwood reported zero revenue and a net loss of 10.93 million CAD. Operating cash outflow reached 1.76 million CAD, leaving just 2.22 million CAD in the bank. The company itself has acknowledged in regulatory filings that its continued existence depends on achieving future profitability. Share-based compensation of 1.59 million CAD over the same period — though non-cash — dilutes existing holders, while shares issued under a February 2026 debt settlement are subject to a lock-up that expires on June 28. After that date, additional stock could flood the market.

The divergence between narrative and numbers is neatly captured by the stock's annualised 30-day volatility of 144–145%. For a company that has spent 114,000 US dollars on paid media placements while earning not a cent of revenue, such gyrations are hardly surprising. The next concrete catalyst arrives on June 28, when the lock-up on the debt-settlement shares lifts — a date that will test whether Redwood's strategic momentum can outweigh the weight of cash burn and dilution.